Drugs / LC28-0126
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03196804 | Jun → Nov 2017 | — | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT01737424 | Dec 2012 → Sep 2013 | — | LG Life Sciences | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02770664 | Apr 2016 → Aug 2018 | ST-elevation myocardial infarction | LG Life Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT02070471 | Jan 2014 → Jun 2015 | ST-elevation myocardial infarction | LG Life Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LC28-0126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02770664 ↗ |
| Route | Intravenous | “LC28-0126(IV)” NCT01737424 ↗ |